Several preclinical investigations of VSV-hIFNβ-NIS have been performed in acute myeloid leukemia (AML) models, as recent preclinical and clinical studies have demonstrated the significant therapeutic value of OV against hematologic malignancies [145,147,148]. The gene discussed is SLC5A5; the disease is acute myeloid leukemia.